REG - RUA Life Sciences - Appointment of Nominated Adviser and Broker

Rua Life SciencesAnnouncement

19/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220519:nRSS0094Ma&default-theme=true

RNS Number : 0094M  RUA Life Sciences PLC  19 May 2022

19 May 2022

 

RUA Life Sciences Plc

 

("RUA Life Sciences", the "Company" or the "Group")

Appointment of Nominated Adviser and Sole Broker

RUA Life Sciences, the holding company of a group of medical device businesses
focused on the exploitation of the patented long-term implantable biostable
polymer, announces it has appointed Cenkos Securities plc as the Company's
nominated adviser and sole broker with immediate effect.

 

Cenkos Securities plc has been the Company's joint broker since December 2020.

 

 

For further information contact:

 

RUA Life Sciences plc

Bill Brown, Chairman
 
    Tel: +44 (0) 77 3071 8296

Caroline Stretton, Group Managing Director
                             Tel: +44 (0) 7789 901269

 

Cenkos Securities plc (Nominated Adviser and Broker)
                                 Tel: +44 (0)
20 7397 8900

Giles Balleny/Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

 

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life
Sciences Plc (formerly known as AorTech International Plc) acquired RUA
Medical Devices Limited to create a fully formed medical device business. RUA
Life Sciences is the holding company of the Group's four trading businesses,
each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and
enabling medical devices with Elast-Eon(TM), the world's leading long-term
implantable polyurethane.

Whether it is licensing Elast-Eon(TM), manufacturing a device or component or
developing next generation medical devices, a RUA Life Sciences business is
pursuing our vision.

 

Elast-Eon™'s biostability is comparable to silicone while exhibiting
excellent mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic extrusion and
moulding techniques. With over 8 million implants and over 15 years of
successful clinical use, RUA's polymers are proven in long-term life enabling
applications.

 

The Group's four business units are:

 RUA Medical:           End-to-end contract developer and manufacturer of medical devices and
                        implantable fabric specialist.
 RUA Biomaterials:      Licensor of Elast-Eon(TM) polymers to the medical device industry.
 RUA Vascular:          Commercialisation of open surgical vascular grafts and patches

 RUA Structural Heart:  Development of polymeric leaflet systems for heart valves.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPAPMFTMTBBBLT